Testing effectiveness (Phase 2)Study completedNCT01853878
What this trial is testing
Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 137